CoChat

Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics

Open access
Spacova, Irina, Binda, Sylvie, ter Haar, Jessica Anne, Henoud, Solange, Legrain-Raspaud, Sophie, Dekker, James, Espadaler-Mazo, Jordi, Langella, Philippe, Martín, Rebeca, Pane, Marco, Ouwehand, Arthur C. · 2023 · Frontiers in Microbiology

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Application of beneficial microorganisms as probiotics targets a broad range of intended uses, from maintaining health and supporting normal bodily functions to curing and preventing diseases. Currently, three main regulatory fields of probiotic products can be defined depending on their intended use: the more similar probiotic foods and probiotic dietary supplements, and live biotherapeutic products. However, it is not always straightforward to classify a probiotic product into one of these categories. The regulatory nuances of developing, manufacturing, investigating and applying each category of probiotic products are not universal, and not always apparent to those unfamiliar with the various global probiotic regulatory guidelines. Various global markets can be significantly different regarding legislation, possible claims, market value and quality requirements for the development and commercialization of probiotic products. Furthermore, different probiotic product categories are also linked with variable costs at different stages of product development. This review outlines the current landscape comparing probiotic foods, probiotic dietary supplements, and live biotherapeutics as probiotic products from a regulatory lens, focusing on product development, manufacturing and production, and clinical research agenda. The aim is to inform and promote a better understanding among stakeholders by outlining the expectations and performance for each probiotic product category, depending on their intended use and targeted geographical region.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2023.1272754

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Overview of main regulatory categories of probiotics (PF, PDS, LBPs). Of note, the use of PF and PDS is not excluded in a diseased individual to support health for similar purposes as in healthy individuals, however here we emphasize the target population from a regulatory perspective. Elaborated by the authors from various sources.
FIGURE 1 Overview of main regulatory categories of probiotics (PF, PDS, LBPs). Of note, the use of PF and PDS is not excluded in a diseased individual to support health for similar purposes as in healthy individuals, however here we emphasize the target population from a regulatory perspective. Elaborated by the authors from various sources.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 18

  1. 2023, Current Good Manufacturing Practices (CGMPs).
  2. Chieffi, 2022, Legislation of probiotic foods and supplements. Probiotics for human nutrition in health and disease.
  3. 1994, S.784 - Dietary Supplement Health and Education Act of 1994. 103rd Congress (1993-1994).
  4. 2007, Corrigendum to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods., Official J. Eur. Union, 12
  5. 2017, Hazard Analysis and Critical Control Point (HACCP).
  6. 2022, H.R.2617 - Consolidated Appropriations Act, 2023.
  7. 2023, Reimbursement of Pharmaceuticals.
  8. 2023, Probiotics.
  9. 2023, Do you know what probiotics are?
  10. 2021, Explained: The US E-commerce probiotic supplements market.
  11. 2023, Hazard Analysis and Critical Control Points (HACCP) understanding HACCP food safety standards.
  12. Paraskevakos, 2020, Global overview for probiotics: trends, markets, and harmonization. Regulatory Focus.
  13. 2019, Live biotherapeutic products for human use 3053 monograph., Eur. Pharmacopoeia, 9, 6522
  14. 2001, Grants and contracts for development of drugs for rare diseases and conditions.
  15. 2016, Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information. Guidance for Industry.
  16. 2021, Facts About the Current Good Manufacturing Practices (CGMPs).
  17. Authorized health claims that meet the Significant Scientific Agreement (SSA) Standard.
  18. Investigational New Drug (IND) application.

Cited by

See all 130

Metadata

Authors
Spacova, I., Binda, S., ter Haar, J. A., Henoud, S., Legrain-Raspaud, S., Dekker, J., Espadaler-Mazo, J., Langella, P., Martín, R., Pane, M., & Ouwehand, A. C.
Affiliations
  • University of Antwerp (BE)
  • Fonterra (New Zealand) (NZ)
  • AgroParisTech (FR)
  • Probiotical (Italy) (IT)
Corresponding author
  • Spacova, Irina
  • Ouwehand, Arthur C.
Venue
Frontiers in Microbiology
Published
2023-12-19
Volume
14
Issue
3
Pages
1272754-1272754
ISSN
1664-302X (ISSN-L)
OpenAlex
W4389938247
Cited by
129
References
50
Citations by year
2026: 68 · 2025: 47 · 2024: 14
FWCI
2.98
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fonds Wetenschappelijk Onderzoek (1277222N)
  • Vlaamse regering
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Agricultural safety and regulations
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Consumer Attitudes and Food Labeling
Keywords
probiotics, probiotic foods, live biotherapeutic products, probiotic regulation, regulatory guidelines, product development, clinical research, health claims, commercialization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics. https://app.cochat.ai/papers/10.3389/fmicb.2023.1272754
The paper
Spacova, I., Binda, S., ter Haar, J. A., Henoud, S., Legrain-Raspaud, S., Dekker, J., Espadaler-Mazo, J., Langella, P., Martín, R., Pane, M., & Ouwehand, A. C. (2023). Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2023.1272754

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.